Regen BioPharma Inc (RGBP) stock
RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026Market cap $92.33KP/E –Yield –
Regen BioPharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Regen BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$445.25K. For fiscal 2025 it was -$383.59K. The highest annual figure on record is $18.65K in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$383.59K | – |
| FY2024 | Sep 30, 2024 | -$751.54K | – |
| FY2023 | Sep 30, 2023 | -$173.92K | – |
| FY2022 | Sep 30, 2022 | -$606.92K | – |
| FY2021 | Sep 30, 2021 | -$1.13M | -6165.6% |
| FY2020 | Sep 30, 2020 | $18.65K | – |
| FY2019 | Sep 30, 2019 | -$481.79K | – |
| FY2018 | Sep 30, 2018 | -$1.58M | – |
| FY2017 | Sep 30, 2017 | -$1.89M | – |
| FY2016 | Sep 30, 2016 | -$1.67M | – |
| FY2015 | Sep 30, 2015 | -$1.19M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$24.07K | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$63.23K | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$197.94K | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$160.01K | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$55.98K | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$101.23K | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$66.38K | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$207.29K | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$172.59K | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$209.32K | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$162.34K | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$23.41K | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$87.01K | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$53.04K | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$10.46K | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$85.29K | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$123.68K | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$118.82K | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$279.14K | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$1.07M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$63.92K | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $0 | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $0 | -100.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $0 | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $0 | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$5.66K | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $24.30K | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$136.96K | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$67.29K | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$127.51K | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$150.03K | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$465.64K | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$81.43K | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$403.51K | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$627.27K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$623.02K | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$417.21K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$349.90K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$504.30K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$398.50K | – |
See a number that looks wrong?